当前位置:首页 - 行情中心 - 美农生物(301156) - 财务分析 - 利润表

美农生物

(301156)

  

流通市值:15.07亿  总市值:23.78亿
流通股本:8922.50万   总股本:1.41亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入390,128,929.24236,148,962.5599,852,532.57489,929,618.41
  营业收入390,128,929.24236,148,962.5599,852,532.57489,929,618.41
二、营业总成本348,508,534.53212,049,945.5691,829,115.62437,284,342.38
  营业成本270,491,707.07165,724,869.8271,735,848.19348,751,374
  利息支出000-
  手续费及佣金支出000-
  退保金000-
  赔付支出净额000-
  提取保险合同准备金净额000-
  保单红利支出000-
  分保费用000-
  税金及附加2,867,103.171,873,653.911,009,706.432,780,018.56
  销售费用30,637,973.2418,894,030.477,846,071.0838,297,378.76
  管理费用29,280,094.0816,550,055.867,553,145.8731,622,992.24
  研发费用16,235,575.6910,256,679.454,546,502.1120,882,512.84
  财务费用-1,003,918.72-1,249,343.95-862,158.06-5,049,934.02
  其中:利息费用5,289.164,965.722,469.43-37,460.23
  其中:利息收入1,448,410.941,030,217.14436,248.452,913,299.39
三、其他经营收益
  加:公允价值变动收益-586,922.96-107,596.46-70,896.811,317,711.16
  加:投资收益2,607,327.781,345,543.15289,668.72384,468.34
  净敞口套期收益000-
  汇兑收益000-
  资产处置收益2,189.662,189.662,189.66353,738.08
  资产减值损失(新)-1,204,064.02-1,029,878.98-611,310.57-1,361,351.3
  信用减值损失(新)177,217.3520,293.271,676,312.29-1,389,694.13
  其他收益2,841,271.041,219,752.4340,645.752,568,710.37
四、营业利润45,457,413.5126,049,320.039,650,025.9954,518,858.55
  加:营业外收入427,915.56193,915.56166,139.531,500,003.28
  减:营业外支出112,011.5858,541.0420,371.8220,004.76
五、利润总额45,773,317.4926,184,694.559,795,793.7255,798,857.07
  减:所得税费用4,855,127.982,657,660.31912,440.296,216,324.62
六、净利润40,918,189.5123,527,034.248,883,353.4349,582,532.45
(一)按经营持续性分类
  持续经营净利润40,918,189.5123,527,034.248,883,353.4349,582,532.45
(二)按所有权归属分类
  归属于母公司股东的净利润40,918,189.5123,527,034.248,883,353.4349,582,532.45
  扣除非经常损益后的净利润38,474,305.4921,840,624.98,494,599.944,484,267.74
七、每股收益
  (一)基本每股收益0.290.170.060.34
  (二)稀释每股收益0.290.170.060.34
九、综合收益总额40,918,189.5123,527,034.248,883,353.4349,582,532.45
  归属于母公司股东的综合收益总额40,918,189.5123,527,034.248,883,353.4349,582,532.45
公告日期2025-10-282025-08-282025-04-262025-04-26
审计意见(境内)标准无保留意见
TOP↑